Aytu BioPharma to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026
Aytu BioPharma (Nasdaq: AYTU), a pharmaceutical company focused on innovative medicines for complex central nervous system diseases, will participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026.
Rhea-AI Summary
Aytu BioPharma (Nasdaq: AYTU), a pharmaceutical company focused on innovative medicines for complex central nervous system diseases, will participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026.
The virtual webcast begins at 9:15 a.m. ET, with replay available on the conference site and Aytu’s investor relations webpage. Management will also host virtual one-on-one meetings with investors during the event.
Positive
- None.
Negative
- None.
Details
News Market Reaction – AYTU
In the May 19 session, AYTU declined 0.95%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
- Conference date
- May 28, 2026
- Lytham Partners Spring 2026 Investor Conference
- Webcast time
- 9:15 a.m. Eastern
- Scheduled start time for AYTU conference webcast
Historical Context
-
Reported fiscal 2026 Q3 revenue decline and net loss with EXXUA launch ramp.
-
Scheduled Q3 fiscal 2026 results release and accompanying call and webcast.
-
Reported Q2 fiscal 2026 revenue decline, net loss and initial EXXUA launch metrics.
-
Announced timing and access details for Q2 fiscal 2026 results call.
-
Showcased EXXUA Phase 3 data, MDD market size and commercialization economics.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
DENVER, CO / ACCESS Newswire / May 18, 2026 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients, will participate in a webcast presentation and host one-on-one meetings with investors at the Lytham Partners Spring 2026 Investor Conference, taking place virtually on Thursday, May 28, 2026.
Company Webcast
The webcast presentation will take place at 9:15 a.m. Eastern time on Thursday, May 28, 2026. The webcast can be accessed by visiting the conference home page at https://lythampartners.com/spring2026/ or directly at https://app.webinar.net/8p9EoXv752z. The webcast will also be available for replay following the event. It will also be accessible on the Investors section of the Company's website at https://investors.aytubio.com/ under Events & Presentations.
1x1 Meetings
Management will be participating in virtual one-on-one meetings throughout the event. To arrange a meeting with management, please contact Lytham Partners at 1x1@lythampartners.com or register for the event at https://lythampartners.com/spring2026invreg/.
About Aytu BioPharma
Aytu is a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients. The Company's prescription products include EXXUA™ (gepirone) extended-release tablets (see Full Prescribing Information, including Boxed WARNING) for the treatment of major depressive disorder (MDD), and treatments for attention deficit-hyperactivity disorder (ADHD). Aytu is committed to delivering the Company's medications through best-in-class patient access programs that help to enable optimal patient outcomes. For more information, please visit aytubio.com or follow us on LinkedIn.
Contacts for Investors
Ryan Selhorn, Chief Financial Officer
Aytu BioPharma, Inc.
rselhorn@aytubio.com
Robert Blum
Lytham Partners
aytu@lythampartners.com
SOURCE: Aytu BioPharma, Inc.
View the original press release on ACCESS Newswire
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.